syndesi therapeutics ceo

No credit card required. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations. Company profile page for Syndesi Therapeutics SA including stock price, company news, press releases, executives, board members, and contact information Syndesi Therapeutics was established to develop a series of novel, pro-cognitive small molecule SV2A modulators licensed from UCB. Clinical studies at UCB: How are medicines made and tested? AbbVie has bolstered its neuropsychiatric and neurodegenerative portfolio with the acquisition of Belgium-based Syndesi Therapeutics in a deal valued at up to $1 billion. After the sale of Tusk, he joined Droia initially as Venture Partner and then as Partner in the Oncology II Fund. UCB is listed on Euronext Brussels (symbol: UCB). Jonathan Savidges role in Syndesi Therapeutics is CEO, Jonathan Savidges business email address is ****@syndesitherapeutics.com, Jonathan Savidges HQ phone number is ********. Lorem ipsum dolor sit, amet consectetur adipisicing elit. free lookups / month. million verified professionals across 35 million companies. The UK Life Sciences team advised Syndesi Therapeutics and its shareholders on Syndesi's acquisition by AbbVie (NYSE: ABBV). Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement. Seed, Series A, Private Equity), Whether an Organization is for profit or non-profit, General contact email for the organization, Auto-generated name of transaction (e.g. Syndesi Therapeutics SA, a clinical stage biotechnology company developing novel modulators of the synaptic vesicle protein SV2A for the treatment of cognitive impairment, announces results from two Phase I studies of its lead compound SDI-118, supporting further development of this promising molecule. The Syndesi Therapeutics SA management team includes Jonathan Savidge (CEO), John Kemp (Chief Scientific Officer), and Torsten Madsen (Chief Medical Officer). (business & personal). Up to 5 According to the deal, shareholders of Syndesi will receive an upfront payment of $130m from AbbVie. AbbVie announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. February 1, 2018 - 3 minutes. Enter employee name to find & verify emails, phones, social links, etc. There is a major unmet need for new therapies that can . Syndesi Therapeutics SA, a clinical stage biotechnology company developing novel modulators of the synaptic vesicle protein SV2A for the treatment of cognitive impairment, provides an update on the clinical development of its lead molecule, SDI-118, and announces an extension of its series A financing. I agree to receive emails from AroundDeal, and can unsubscribe at any time. Syndesi Therapeutics is in the sectors of: Biotechnology. Country: Belgium. The VIVES Louvain Technology Fund (www.vivesfund.com) is a multi-sector technology fund which invests in the spin-offs of the Universit catholique de Louvain (UCL) and start-ups in Belgium and neighboring countries. Find contact info for Syndesi Therapeutics SA employees. Jonathan Savidge works for Syndesi Therapeutics. With the support of our investors and other stakeholders, Syndesi's goal is to demonstrate the potential of these molecules to reduce the symptoms of cognitive impairment in patients with Alzheimer's Disease . Syndesi will build on a rich legacy of work by UCB to further develop these novel SV2A modulators to investigate their potential to improve cognition in diseases such as Alzheimers Disease, other dementias and cognitive impairment associated with schizophrenia. Driven by science. About Syndesi Therapeutics. Jonathan Savidge is the CEO at Syndesi Therapeutics based in United Kingdom. Syndesi's unique molecules act pre-synaptically to enhance synaptic efficiency by . Address: Centre d'Entreprises et d'Innovation (CEI) Incubator Chemin du Cyclotron 6 1348 Louvain-la-Neuve Belgium. 17,000,000 Venture capital (Series A) FierceBiotech. Type Private Founded 2018 HQ Prior to teaming up with Droia, Luc was the CEO of Tusk Therapeutics from 2015 until it was sold to Roche in 2018. Its current portfolio fair value is above 150 million . Philippe Durieux, CEO of Sopartec, the management company of VIVES: "The acquisition of Syndesi by Abbvie illustrates our ability of creating bridges between science and industry. The fund invests throughout Europe in start-up and early-stage companies with high growth potential focusing on technologies that provide transformational improvements in the biopharmaceutical, pharmaceutical, diagnostics and agricultural sectors. Syndesi Therapeutics Contact Information. A regenerative therapy company - Bone Therapeutics Bone Therapeutics is an advanced biotechnology company with a unique approach to the development of cell therapy products for orthopaedics and bone diseases. All rights reserved. V-Bio Ventures was established in 2015 and works closely with Belgium-based VIB, one of the worlds premier life science institutes. Syndesi Therapeutics's key executives include Jonathan Savidge and 6 others. In addition to being the major shareholder in the Novo Group companies, Novo Holdings provides seed and venture capital to development-stage companies, takes significant ownership positions in well-established companies within the life sciences and manages a broad portfolio of financial assets. UCB identified novel modulators of SV2A that show pro-cognitive properties in preclinical models. Syndesi Therapeutics is developing molecules that modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). All rights reservedLast updated on:January, 28, 2022, Syndesi Therapeutics is based in Belgium and will leverage UCBs neurology expertise in modulating the synaptic vesicle protein SV2A. Syndesi benefits both from UCBs research expertise and from an impressive syndicate of experienced investors and their respective networks., Cognitive impairment remains an area of significant unmet need for patients not only with Alzheimers Disease but also more broadly across a range of neurological disorders, and we are excited about the potential promise of this novel therapeutic approach, says Morten Graugaard Dssing, Principal at Novo Seeds. Get Contact Info for All Departments March 01, 2022. Chief Executive Officer and Technical Lead, Associate Director, Asia Pacific Logistics. Novo Seeds is the early-stage investment arm of Novo Holdings (www.novoholdings.dk). Enter your email to download the profile. WhatsApp acquired by Facebook). Syndesi Therapeutics has been formed by UCB and a group of investors, including Novo Seeds and V-Bio to develop a group of compounds for cognitive disorders caused by diseases like Alzheimer's. Syndesi Therapeutics will use of Belgian biotech UCB's expertise in drug discovery for neurological conditions to . 2007 -2022 UCB S.A., Belgium. Lorem ipsum dolor sit amet consectetur adipisicing elit. Find More Contacts for Syndesi Therapeutics, Edit Lists Featuring This Company Section, Novo Holdings Portfolio Company Syndesi Therapeutics acquired by AbbVie, Syndesi Therapeutics Announces Positive Results From Two Additional Phase I Studies Of Its Novel SV2A modulator SDI-118. Fountains main office is in Dublin, Ireland, with a second office in New York. UCB spins out neuro startup with 17M from Novo, Johnson & Johnson Syndesi Therapeutics. The mechanism is currently being evaluated . In the life science sector, SRIW is investor in more than 30 companies such as I.B.A., Celyad, or Ogeda of which it recently exited. Show more Syndesi Therapeutics headquarters is in Louvain-la-Neuve, Walloon Region. T+32.2.559.9588, isabelle.ghellynck@ucb.com. You'll receive an email shortly. The Company's approach is aimed at treating Alzheimer's Disease and other disorders with cognitive impairment. CEO at Syndesi Therapeutics. Syndesi Therapeutics. According to the terms of the $1bn agreement, Abbvie will pay Syndesi an upfront payment of $130m, with milestone payments of up to $870m. Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. Morten Graugaard Dssing Board Member Feb 2018 Christina Takke Board Member Dec 2017 Find contact info for Syndesi Therapeutics SA employees. {{ userNotificationState.getAlertCount('bell') }}. Lorem ipsum dolor sit amet consectetur adipisicing elit. Jonathan Savidge is the CEO at Syndesi Therapeutics based in United Kingdom. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. With the support of our investors and other stakeholders, Syndesi's goal is to demonstrate the potential of these molecules to reduce the symptoms of cognitive impairment in patients with Alzheimer's Disease . Syndesi Therapeutics develops a drug candidate for the treatment of consecutive cognitive disorders of various neurological conditions. The mechanism is currently being evaluated for . Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed. Syndesi Therapeutics SA employs 23 employees. www.jjdc.com. SaaS, Android, Cloud Computing, Medical Device), Where the organization is headquartered (e.g. Syndesi Therapeutics is building upon a rich legacy of research on SV2A conducted at UCB. (business & personal). Johnson & Johnson Innovation JJDC Inc. (JJDC) is the strategic venture capital arm of Johnson & Johnson and a long-term investment partner to global healthcare entrepreneurs. This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. The company is the holding company in the Novo Group, comprising Novo Nordisk A/S, Novozymes A/S and NNIT A/S, and is responsible for managing the Foundations assets. Sharing his thoughts on the deal, Tom Hudson, senior vice president, R&D, chief scientific officer, AbbVie, said: "There is a major unmet need for new therapies that can help improve cognitive function in . Syndesi Therapeutics is building upon a rich legacy of research on SV2A conducted at UCB. Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. Back to companies Company name Syndesi Therapeutics Location Louvain-la-neuve Belgium CEO Jonathan Savidge Website Contact Information Website www.syndesitherapeutics.com Ownership Status Acquired/Merged Financing Status Formerly VC-backed Primary Industry Drug Discovery Other Industries Biotechnology Acquirer AbbVie Primary Office Chemin du Cyclotron 6 1348 Ottignies-Louvain-la-Neuve Belgium +32 010 00 00 00 Want detailed data on 3M+ companies? UCB - Inspired by patients. ABBV ie (NYSE: ABBV) today announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand ABBV ie's neuroscience portfolio. If you have any question, email us support@arounddeal.com. UCB and investor syndicate led by Novo Seeds launch Syndesi Therapeutics to develop novel therapeutics for cognitive disorders, 2007 - 2022UCB S.A., Belgium. Regulating synaptic transmission represents a promising approach to treating Alzheimer's Disease and other disorders with cognitive impairment. Jonathan Savidge colleagues are Steven Ramael,John Kemp. This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI 118. Syndesi has an exclusive license to its platform technology from UCB, the leading company in SV2A research. About Bone Therapeutics Jonathan Savidge, PhD CEO of Syndesi noted: "Development of these small molecules that modulate the SV2A target in a distinct manner represents an intriguing new approach for the treatment of . Monday: 9am - 5pm; Tuesday: 9am - 5pm; Wednesday: 9am - 5pm; Thursday: 9am - 5pm . jonathan savidge, phd ceo of syndesi noted "development of these small molecules that modulate the sv2a target in a distinct manner represents an intriguing new approach for the treatment of cognitive deficits since they specifically target synaptic dysfunction, a hallmark of alzheimer's disease and other indications characterized by cognitive The funds (VIVES I - 15 million and VIVES II - 43 million) are managed by SOPARTEC, UCLs technology transfer company, member of the Louvain Technology Transfer Office. About Syndesi Therapeutics Founded in December 2017 . UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases in immunology and neurology. Regulating synaptic transmission represents a . AbbVie announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. Follow us on Twitter: @UCB_news. AbbVie will pay Syndesi's shareholders a $130 million upfront payment with the potential for Syndesi's shareholders to receive additional contingent payments of up to $870 million based on the achievement of certain predetermined milestones. No credit card required. Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Search over 700 Contact Email info@syndesitherapeutics.com Phone Number +32 10 280 238 Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). The Belgian life science ecosystem is particularly vibrant and we realised that it was the right environment to promote this research as part of our biotech model approach., Jonathan Savidge, PhD CEO of Syndesi noted Development of these small molecules that modulate the SV2A target in a distinct manner represents an intriguing new approach for the treatment of cognitive deficits since they specifically target synaptic dysfunction, a hallmark of Alzheimers Disease and other indications characterized by cognitive impairment. Active, Closed, Last funding round type (e.g. Regulating the synaptic transmission is a promising approach to treat Alzheimer's disease and other disorders with cognitive impairment. Up to 5 Syndesi Therapeutics is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment seen in multiple CNS disorders, including Alzheimers Disease, schizophrenia and depresson. This acquisition gives . SRIW Socit Rgionale d'Investissement de Wallonie (www.sriw.be) provides equity and/or debt to companies that generate added value and employment in Wallonia. Novo Holdings is a private limited liability company wholly owned by the Novo Nordisk Foundation. With an upfront payment of $130 million, AbbVie gains Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Search over 700 The firm deploys the majority of its capital in Europe, with the balance in the United States. Regulating synaptic transmission represents a promising approach to treating Alzheimers Disease and other disorders with cognitive impairment. . read more 10 Dec With more than 7500 people in approximately 40 countries, the company generated revenue of 4.2 billion in 2016. free lookups / month. {{ userNotificationState.getAlertCount('bell') }}. Developing novel SV2A modulators as potential treatments for cognitive impairment | Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the bra. This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. About Syndesi Therapeutics. Unlike, UCB is the world leader in SV2A research, having discovered and developed two major anti-epileptic drugs treating patients around the world. Syndesi Therapeutics | 837 followers on LinkedIn. Get Jonathan Savidges Contact Info Syndesi Therapeutics (www.syndesitherapeutics.com) has been established at the Centre dEntreprises et dInnovation (CEI) in Louvain-la-Neuve and will have a presence at the JLINX incubator facilities to access expertise at the Janssen campus in Beerse, Belgium. AbbVie has acquired Belgium-based company Syndesi Therapeutics in a deal worth up to $1bn, expanding its neuroscience portfolio. Thank you for your order. Call our Sales Team men's combined olympics 2022 results Thursday : 9am - 5pm. Disclosure of payments to Healthcare Professionals. Region: Europe. Jonathan Savidges email address is ****@syndesitherapeutics.com, Jonathan Savidges direct phone number is ********. Stay up-to-date on the latest news and information from UCB, 2007 - 2022UCB S.A., Belgium. Founded in 1973, JJDC continues a legacy of customizing deals for data-driven companies across the continuum of healthcare, with the goal of turning great ideas into transformative new pharmaceutical, medical device and consumer healthcare products. Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Regulating synaptic transmission represents a promising . If you have any question, email us support@arounddeal.com. Jonathan Savidge works in the industry of Biotechnology. See more information about Jonathan Savidge. Founding CEO at Syndesi Therapeutics (now an AbbVie Company) Greater Oxford Area 1K followers 500+ connections Join to connect AbbVie The University of Manchester About - 20 years of. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. Lorem ipsum dolor sit, amet consectetur adipisicing elit. Syndesi Therapeutics's Chief Executive Officer is Jonathan Savidge. Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). CEO of Syndesi, said "We very much appreciate the Walloon Region's ongoing support for the continued . Name of the organization that made the acquisition, Total amount raised across all funding rounds, Total number of Crunchbase contacts associated with this organization, Total number of employee profiles an organization has on Crunchbase, Total number of investment firms and individual investors, Total number of organizations similar to the given organization, Descriptive keyword for an Organization (e.g. Syndesi has an exclusive, worldwide license from UCB to develop and commercialise a series of novel, pro-cognitive SV2A modulators. I am delighted with the announcement of this deal. Enter your email to download invoice. Get contact details including emails and phone numbers million verified professionals across 35 million companies. Jonathan Savidge CEO of Syndesi said . UCBs Neuroscience researchers in Belgium have designed a unique class of novel SV2A modulators. VIVES II is funded by a dozen leading Belgian and European investors such as the EUROPEAN INVESTMENT FUND (EIF), SFPI-FPIM, BNP PARIBAS FORTIS PRIVATE EQUITY BELGIUM, BPI FRANCE (France), ING BELGIUM, SOFINA, AXA BELGIUM, BELFIUS, IRD (France), NIVELINVEST, REGION BRUXELLES CAPITAL and by SOPARTEC. Syndesi is investigating the potential of these molecules to improve cognition in diseases such as Alzheimer's Disease and other dementias, as well as other conditions such as major depression and cognitive impairment associated with schizophrenia. They are also entitled to get further contingent payments of up to $870m on meeting specific pre-set milestones. SRIW facilitates the region's economic development, contributing effectively to the modernisation, growth and restructuring of the businesses that make up the Walloon industrial network. We are excited to see Syndesi develop our novel pro-cognitive SV2A modulators to create value for patients with cognitive impairment, said Dhavalkumar Patel, UCBs Chief Scientific Officer and Executive Vice President. 01 Mar 2022. Fountain Healthcare Partners (www.fh-partners.com) is a life science focused venture capital fund with 176 million ($200 million) under management. "With AbbVie's acquisition of Syndesi, we aim to advance the research of a novel, first-in-class asset for the potential treatment of cognitive impairment associated with neuropsychiatric and. The objective of the fund is to invest in the development of start-ups, from validation of the technology to commercial maturity. Get contact details including emails and phone numbers Sign up for a free account. Jonathan Savidge, Chief Executive Officer, Syndesi Therapeutics, said: "We have been impressed with the vision of AbbVie's neuroscience R&D team, who share our view on the therapeutic potential of SDI-118 in a range of neurologic diseases. Syndesi's unique molecules act pre-synaptically to enhance synaptic efficiency by positively modulating the function of . All rights reserved. Novo Holdings A/S (formerly Novo A/S) is the Novo Nordisk Foundation's wholly owned holding company for Novo Nordisk A/S and Novozymes A/S.Novo Holdings A/S was established in 1999 and manages the Novo Nordisk Foundation's assets, which in 2021 was worth almost DKK 700 billion Danish Kroner (approximately US$93.73 billion) and is the largest charitable foundation in the world making Novo . . Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic . SV2A plays a central role in synaptic transmission (connections between neurons). Within the life science sector, specific areas of interest to Fountain include specialty pharma, medical devices, biotechnology and diagnostics. . Alzheimer's Therapeutics Research Leader Dr. Roy Twyman Joins NeuroVision Imaging Board Twyman Served as Senior Vice President at Janssen Pharmaceutical Research & Development, Overseeing . Enter employee name to find & verify emails, phones, social links, etc. Ferrous(II) glycine sulphate complex (Ferro Sanol), Plain language summaries of study results, Access to Patient-Level Clinical Study Data, Plain Language Summaries of research results, Registration and Results Reporting on Public Registries, Cimzia - Axial spondyloarthritis (axSpA), Privacy Policy for Healthcare Professionals, Syndesi Therapeutics to leverage UCBs expertise in neurology drug discovery to develop potential therapeutics in cognitive disorders with a first-in-class mechanism, Series A financing of 17 M from a syndicate of Belgian and international investors. Stage: Acquired Total Funds Raised: $20.8M Status: ACQUIRED Syndesi Therapeutics awarded non-dilutive funding of up to 3.2M for development of its lead program, SDI-118, aimed at treating cognitive impairment Belgium - 20 March 2019 - Syndesi Therapeutics SA, a biotechnology company . CEO of Syndesi, . Luc is co-founder of two genetic disease companies, Pharvaris and Vico. Jonathan Savidge Chief Executive Officer John Kemp Chief Scientific Officer Torsten Madsen Chief Medical Officer Maeve Duffy Head of Clinical Operations Steven Ramael Medical Director Jean Combalbert

Sadhguru Sun And Moon, Beaver Dam Trail Hilton Falls, The Ridge Apartments Austin, Toadally Awesome Reprint, Icse Study Guide Class 7 Chemistry, Ex Girlfriend Wants Me Back After I Moved On, Houses In Princeton, Tx For Sale, Concerts In Athens, Ga 2022, Cheap Beach Houses For Sale In South Carolina, Degrees Of Comparison Of Adjectives Exercises, Tally's Dockside Drink Menu, Motocross 2022 Standings,